The first examination of a brain from a patient enrolled in a halted clinical trial for an Alzheimer disease (AD) vaccine reveals striking—and potentially dangerous—effects.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cerebral microbleeds: overview and implications in cognitive impairment
Alzheimer's Research & Therapy Open Access 11 June 2014
-
What does complement do in Alzheimer’s disease? Old molecules with new insights
Translational Neurodegeneration Open Access 12 October 2013
-
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
BMC Neurology Open Access 13 January 2009
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kimberly Homer
References
McGeer, P.L., Schulzer, M. & McGeer, E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425–432 (1996).
Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Bacskai, B.J. et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369–372 (2001).
McLaurin, J. et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263–1269 (2002).
Nicoll, J.A.R. et al. Neuropathology of human Alzheimer's disease following immunization with amyloid β-peptide. Nat. Med. 9; advance online publication 17 March 2003; doi:10.1038/nm840.
Check, E. Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462 (2002).
Eng, J.A., Frosch, M.P. & Greenberg, S.M. Cerebral amyloid angiopathy-related inflammation, subacute cognitive decline, and reversible white matter changes. Stroke 34, 275 (2003).
Engler, H. et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiol. Aging 23 (suppl. 1), S429 (2002).
Bacskai, B.J. et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 7873–7878 (2002).
Pfeifer, M. et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298, 1379 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Greenberg, S., Bacskai, B. & Hyman, B. Alzheimer disease's double-edged vaccine. Nat Med 9, 389–390 (2003). https://doi.org/10.1038/nm847
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm847
This article is cited by
-
Cerebral microbleeds: overview and implications in cognitive impairment
Alzheimer's Research & Therapy (2014)
-
What does complement do in Alzheimer’s disease? Old molecules with new insights
Translational Neurodegeneration (2013)
-
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
BMC Neurology (2009)
-
Experimental therapeutics in transgenic mouse models of Huntington's disease
Nature Reviews Neuroscience (2004)
-
Fighting fire with fire
Nature Reviews Neuroscience (2003)
